A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION

Chrysalis Biotherapeutics，Inc.是开创性的使用天然肽再生信号，恢复正常的干细胞群，以防止长期损伤，缺血，辐射。在本合同中，他们将进一步开发他们的产品TP 508，一种凝血酶肽，通过在急性辐射的急性和延迟效应的已建立小鼠和猪模型中获得疗效数据、病理生理学和药理学数据，以支持动物规则IND和许可，并在本项目结束时启动关键动物研究。TP508是一种重新利用的产品，已经在人体临床试验中用于皮肤和肌肉骨骼修复。

Chrysalis Biotherapeutics, Inc. is pioneering the use of natural peptide regenerative signals that restore normal stem cell populations to prevent long-term damage from injury, ischemia, and radiation. In this contract they will further develop their product, TP508, a thrombin peptide by obtaining efficacy data, pathophysiological and pharmacometric data in established murine and porcine models of acute and delayed effects of acute radiation to support Animal Rule IND and licensure and initiate pivotal animal studies at the end of this project. TP508 is a repurposed product already in human clinical trials for dermal and musculoskeletal repair.